Get startedLog in
    Picture of Annexin Pharmaceuticals AB (publ) logo

    ANNX — Annexin Pharmaceuticals AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Annexin Signs Exclusive Licensing Deal In Cancer

    Picture of Annexin Pharmaceuticals AB (publ) logoAnnexin Pharmaceuticals AB (publ)
    03/04/2022 20:06
    April 3 (Reuters) - Annexin Pharmaceuticals AB (publ)
 ANNX.ST :
    * ANNEXIN SIGNS EXCLUSIVE LICENSING DEAL IN CANCER
    * ANNEXIN-ENTERED INTO A LICENSE AGREEMENT WITH STANFORD
UNIVERSITY, CA, USA GRANTING CO EXCLUSIVE LICENSE TO PATENT
RIGHTS RELATED TO USE OF ANNEXIN A5
    * LICENSE INVOLVES A NOVEL THERAPEUTIC CONCEPT FOR TREATING
CANCER
BY ADMINISTRATION OF ANNEXIN A5 PROTEIN

Source text for Eikon:  ID:nWkr4xd2gB 
Further company coverage:  ANNX.ST 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Annexin Pharmaceuticals AB (publ)

    See all news